These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30901208)

  • 41. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
    Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L
    J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
    Yoo J; Kim SJ; Son D; Seo H; Baek SY; Maeng CY; Lee C; Kim IS; Jung YH; Lee SM; Park HJ
    Eur J Med Chem; 2016 Jun; 116():126-135. PubMed ID: 27060764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.
    Zhang X; Bao B; Yu X; Tong L; Luo Y; Huang Q; Su M; Sheng L; Li J; Zhu H; Yang B; Zhang X; Chen Y; Lu W
    Bioorg Med Chem; 2013 Nov; 21(22):6981-95. PubMed ID: 24095018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Han L; Wang L; Hou X; Fu H; Song W; Tang W; Fang H
    Bioorg Med Chem; 2014 Mar; 22(5):1529-38. PubMed ID: 24525003
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with L-phenylglycine scaffold.
    Zhang Y; Li X; Hou J; Huang Y; Xu W
    Drug Des Devel Ther; 2015; 9():5553-67. PubMed ID: 26504374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
    Sun Q; Yao Y; Liu C; Li H; Yao H; Xue X; Liu J; Tu Z; Jiang S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3295-9. PubMed ID: 23601706
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
    Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
    ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination.
    Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
    Apoptosis; 2020 Jun; 25(5-6):370-387. PubMed ID: 32394008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histone deacetylase inhibitors in the treatment of hematological malignancies.
    Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
    Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.
    Chen C; Li X; Zhao H; Liu M; Du J; Zhang J; Yang X; Hou X; Fang H
    J Med Chem; 2022 Feb; 65(4):3667-3683. PubMed ID: 35152694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of a dual-target DYRK2 and HDAC8 inhibitor for the treatment of hepatocellular carcinoma.
    Zhang L; Guan L; Wang Y; Niu MM; Yan J
    Biomed Pharmacother; 2024 Aug; 177():116839. PubMed ID: 38889633
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of side-chain changes on histone deacetylase inhibitory and cytotoxicity activities of curcuminoid derivatives.
    Somsakeesit LO; Senawong T; Kumboonma P; Saenglee S; Samankul A; Senawong G; Yenjai C; Phaosiri C
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127171. PubMed ID: 32273215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
    Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
    Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
    Wu S; Huang Y; Wang T; Li K; Lu J; Huang M; Dong G; Sheng C
    J Med Chem; 2022 Mar; 65(6):4818-4831. PubMed ID: 35238576
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
    Patil V; Sodji QH; Kornacki JR; Mrksich M; Oyelere AK
    J Med Chem; 2013 May; 56(9):3492-506. PubMed ID: 23547652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer.
    Wan G; Feng Z; Zhang Q; Li X; Ran K; Feng H; Luo T; Zhou S; Su C; Wei W; Wang N; Gao C; Zhao L; Yu L
    J Med Chem; 2022 Dec; 65(24):16541-16569. PubMed ID: 36449947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.